Photothermal Nanozymatic Nanoparticles Induce Ferroptosis and Apoptosis through Tumor Microenvironment Manipulation for Cancer Therapy

Small. 2022 Oct;18(41):e2202161. doi: 10.1002/smll.202202161. Epub 2022 Sep 11.

Abstract

It is highly desirable to design a single modality that can simultaneously trigger apoptosis and ferroptosis to efficiently eliminate tumor progression. Herein, a nanosystem based on the intrinsic properties of tumor microenvironment (TME) is designed to achieve tumor control through the simultaneous induction of ferroptosis and apoptosis. CuCP molecules are encapsulated in a liposome-based nanosystem to assemble into biocompatible and stable CuCP nanoparticles (CuCP Lipo NPs). This nanosystem intrinsically possesses nanozymatic activity and photothermal characteristics due to the property of Cu atoms and the structure of CuCP Lipo NPs. It is demonstrated that the synergistic strategy increases the intracellular lipid-reactive oxides species, induces the occurrence of ferroptosis and apoptosis, and completely eradicates the tumors in vivo. Proteomics analysis further discloses the key involved proteins (including Tp53, HMOX1, Ptgs2, Tfrc, Slc11a2, Mgst2, Sod1, and several GST family members) and pathways (including apoptosis, ferroptosis, and ROS synthesis). Conclusively, this work develops a strategy based on one nanosystem to synergistically induce ferroptosis and apoptosis in vivo for tumor suppression, which holds great potential in the clinical translation for tumor therapy.

Keywords: catalytic therapy; ferroptosis; nanozymes; photothermal therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Cyclooxygenase 2
  • Ferroptosis*
  • Lipids
  • Liposomes
  • Nanoparticles* / chemistry
  • Neoplasms* / therapy
  • Oxides
  • Reactive Oxygen Species / metabolism
  • Superoxide Dismutase-1
  • Tumor Microenvironment

Substances

  • Lipids
  • Liposomes
  • Oxides
  • Reactive Oxygen Species
  • Cyclooxygenase 2
  • Superoxide Dismutase-1